噬菌體療法市場規模、佔有率和成長分析（按產品、類型、疾病適應症、最終用戶和地區分類）—產業預測（2026-2033 年）

預計到 2024 年，全球噬菌體療法市場規模將達到 3,499 萬美元，到 2025 年將成長至 4,107 萬美元，到 2033 年將成長至 1.4822 億美元，在預測期（2026-2033 年）內複合年成長率為 17.4%。

全球噬菌體療法市場正在擴張，其主要驅動力是應對抗生素抗藥性的迫切需求，抗生素抗藥性對公共衛生構成重大威脅。推動市場成長的關鍵因素包括多重抗藥性細菌感染疾病的普遍存在、對替代抗菌策略投資的增加以及各領域研發投入的活性化。噬菌體療法因其對有害細菌的特異性、對微生物群的保護以及副作用極小而成為一種極具吸引力的替代方案。然而，監管的不確定性、臨床證據的缺乏以及構建個性化噬菌體混合物的複雜性等挑戰依然存在，阻礙了其主流應用。儘管如此，基因組技術的進步以及生物技術公司與學術機構之間合作的加強表明，噬菌體療法在對抗超級細菌和創新抗感染療法方面擁有廣闊的應用前景。

全球噬菌體療法市場促進因素

全球噬菌體療法市場的成長主要受抗菌素抗藥性（AMR）問題日益嚴重的推動。隨著細菌不斷進化並對傳統抗生素產生抗藥性，感染疾病的治療難度也隨之增加。濫用和過度使用這些藥物會加劇抗菌素抗藥性，導致死亡率上升、疾病傳播廣泛以及醫療成本飆升。應對這場公共衛生危機的迫切性日益凸顯，使得噬菌體療法等替代療法備受關注。此外，慢性感染疾病的不斷增加也進一步推動了對能夠有效對抗抗藥性菌株的創新治療方法的需求。

限制全球噬菌體療法市場的因素

全球噬菌體療法市場面臨的一大障礙是缺乏支持其療效和安全性的臨床證據。在該領域進行的許多研究規模有限，通常僅涉及小規模受試者或依賴同情用藥，未能達到大規模隨機對照試驗的嚴格標準。這種缺乏可靠證據的情況削弱了醫療專業人員和監管機構對噬菌體療法的信心。因此，獲得核准、提高醫療服務提供者的接受度以及實現擴充性都面臨許多困難，阻礙了噬菌體療法的有效商業化和整合到現有治療通訊協定中。

全球噬菌體療法市場趨勢

全球噬菌體療法市場正呈現出顯著的趨勢，即整合人工智慧和生物資訊等先進技術，以提高治療的特異性和療效。研發人員正投資於人工智慧驅動的噬菌體宿主預測程序和自動化噬菌體篩檢平台，這些平台能夠簡化開發流程，同時降低相關成本和前置作業時間。這項技術進步不僅能夠提供更快、更精準的治療方案，也符合個人化醫療的發展趨勢。因此，在這些創新技術的推動下，噬菌體療法的廣泛應用有望重塑醫療保健領域應對感染疾病控制和抗生素抗藥性的方式。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 技術進步
• 案例研究
• 專利分析

全球噬菌體療法市場規模（按產品和複合年成長率分類）（2026-2033 年）

• 大腸桿菌
• 金黃色葡萄球菌
• 沙門氏菌
• 銅綠假單胞菌
• 其他

全球噬菌體療法市場規模（按類型和複合年成長率分類）（2026-2033 年）

• 雙鏈DNA噬菌體
• 單股DNA噬菌體
• 單股RNA噬菌體
• 其他

全球噬菌體療法市場規模（按疾病適應症和複合年成長率分類）（2026-2033 年）

• 尿道感染
• 慢性中耳炎
• 慢性潰瘍性大腸炎
• 骨感染疾病
• 傷口和皮膚感染疾病
• 囊腫纖維化
• 其他疾病適應症

全球噬菌體療法市場規模（按最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院和診所
• 研究和學術機構
• 其他

全球噬菌體療法市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Armata Pharmaceuticals（United States）
• BiomX Inc.（Israel）
• Intralytix（United States）
• Locus Biosciences（United States）
• Amplify Biosciences（United States）
• EnBiotix（United States）
• PhagoMed Biopharma（Austria）
• Transgene SA（France）
• Imugene Ltd（Australia）
• Evotec SE（Germany）
• Novolytics（United Kingdom）
• GangaGen Biotechnologies（India）
• Pherecydes Pharma（France）
• Eligo Bioscience（France）
• Micreos（Netherlands）
• ContraFect Corporation（United States）
• Phagomed Biopharma GmbH（Austria）
• PhagePro Inc.（United States）
• TechnoPhage（Portugal）
• Intralytix, Inc.（United States）

結論與建議

Global Phage Therapy Market size was valued at USD 34.99 Million in 2024 and is poised to grow from USD 41.07 Million in 2025 to USD 148.22 Million by 2033, growing at a CAGR of 17.4% during the forecast period (2026-2033).

The global Phage Therapy Market is on the rise, driven by the urgent need to address antibiotic resistance, which poses a significant threat to public health. Key factors fueling market growth include the prevalence of multidrug-resistant bacterial infections, increased investment in alternative antimicrobial strategies, and heightened research and development efforts from various sectors. Phage therapy's specificity for harmful bacteria, preservation of the microbiome, and lack of side effects make it an attractive alternative. However, challenges remain, including regulatory uncertainties, limited clinical evidence, and the complexity of creating tailored phage cocktails, which hinder mainstream adoption. Nevertheless, advancements in genomic technologies and increasing collaborations between biotech firms and academia suggest a promising future for phage therapy in combating superbugs and revolutionizing anti-infective treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Phage Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Phage Therapy Market Segments Analysis

Global Phage Therapy Market is segmented by Product, Type, Disease Indication, End User and region. Based on Product, the market is segmented into Escherichia coli, Staphylococcus aureus, Salmonella, Pseudomonas aeruginosa and Others. Based on Type, the market is segmented into DsDNA Bacteriophage, SsDNA Bacteriophage, SsRNA Bacteriophage and Others. Based on Disease Indication, the market is segmented into Urinary Tract Infections, Chronic Otitis, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis and Other Disease Indications. Based on End User, the market is segmented into Hospital & Clinics, Research & Academic Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Phage Therapy Market

The Global Phage Therapy market is driven by the growing challenge of antimicrobial resistance (AMR), as bacteria evolve and become resistant to conventional antibiotics, rendering infections increasingly difficult to treat. The misuse and overuse of these medications have led to heightened levels of AMR, resulting in greater mortality rates, the spread of diseases, and escalating healthcare costs. As the urgency to address this public health crisis intensifies, alternative treatment modalities such as phage therapy are gaining traction. Additionally, the rising prevalence of chronic infections further fuels the demand for innovative therapeutic options that can effectively combat resistant bacterial strains.

Restraints in the Global Phage Therapy Market

A prominent obstacle in the global phage therapy market is the insufficient clinical evidence supporting its efficacy and safety. Many studies conducted in this field are limited in scope, often involving small participant groups or relying on compassionate use, which do not meet the rigorous standards set by large randomized controlled trials. This lack of robust evidence diminishes the confidence of medical professionals and regulators in phage treatments. Consequently, securing approval, fostering acceptance among healthcare providers, and achieving scalability becomes challenging, hindering the effective commercialization and integration of phage therapy into established treatment protocols.

Market Trends of the Global Phage Therapy Market

The Global Phage Therapy market is witnessing a significant trend towards the integration of advanced technologies such as artificial intelligence and bioinformatics, aimed at enhancing treatment specificity and efficacy. Developers are investing in AI-assisted phage-host prediction programs and automated phage screening platforms, which streamline the development process while reducing associated costs and lead times. This technological advancement not only facilitates quicker and more precise therapeutic options but also aligns with the growing shift towards personalized medicine. Consequently, the increasing adoption of phage therapy reinforced by these innovations is expected to reshape infection management and antibiotic resistance strategies in healthcare.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Case Studies
• Patent Analysis

Global Phage Therapy Market Size by Product & CAGR (2026-2033)

• Market Overview
• Escherichia coli
• Staphylococcus aureus
• Salmonella
• Pseudomonas aeruginosa
• Others

Global Phage Therapy Market Size by Type & CAGR (2026-2033)

• Market Overview
• DsDNA Bacteriophage
• SsDNA Bacteriophage
• SsRNA Bacteriophage
• Others

Global Phage Therapy Market Size by Disease Indication & CAGR (2026-2033)

• Market Overview
• Urinary Tract Infections
• Chronic Otitis
• Chronic Ulcerative Colitis
• Bone Infection
• Wound and Skin Infections
• Cystic Fibrosis
• Other Disease Indications

Global Phage Therapy Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospital & Clinics
• Research & Academic Institutes
• Others

Global Phage Therapy Market Size & CAGR (2026-2033)

• North America (Product, Type, Disease Indication, End User)
  • US
  • Canada
• Europe (Product, Type, Disease Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Type, Disease Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Type, Disease Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Type, Disease Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Armata Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BiomX Inc. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intralytix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Locus Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amplify Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EnBiotix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PhagoMed Biopharma (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transgene S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Imugene Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novolytics (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GangaGen Biotechnologies (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pherecydes Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eligo Bioscience (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Micreos (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ContraFect Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phagomed Biopharma GmbH (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PhagePro Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TechnoPhage (Portugal)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intralytix, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations